Aravax

Aravax is a clinical-stage biotechnology company focused on developing innovative immunotherapies for food allergies.

Founded in May 2015, the company is based in Melbourne, Australia, and has operations in the UK, USA, and Europe. Aravax is privately held and employs a dedicated team of approximately 11 to 50 staff members. The company is supported by a group of prominent investors, including the Novartis Venture Fund and Brandon Capital Partners. The core service of Aravax involves the design and clinical testing of peptide-based immunotherapies that aim to retrain the immune system to tolerate specific food allergens, such as peanuts. Their lead product, PVX108, is currently in Phase 2 trials, targeting peanut allergies in children and adolescents. Aravax is also expanding its pipeline to address additional food allergies, leveraging its proprietary technology platform to create safe and effective treatments for a broader range of allergens.